Funding for this research was provided by:
Pfizer Inc (N/A)
Received: 22 November 2018
Accepted: 26 April 2019
First Online: 28 May 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and ethical principles originating in or derived from the Declaration of Helsinki, approved by the appropriate Institutional Review Boards and Independent Ethics Committees of the investigational centers (Additional file InternalRef removed) and registered on ClinicalTrials.gov (NCT00531479). All patients provided written, informed consent.
: Not applicable.
: JJ, DW, Y-JL, HM, XC, and ISS have nothing to disclose. TFP has received research support from or served on advisory boards/consultant for Astellas, Basilea, Gilead, Merck, Pfizer, Scynexis, and Toyama. YL, SP, JLY, JAA, and XZ are employees of Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.